News
Press Releases
February 25th, 2025
Novita Presents Additional Positive Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at AACR IO Annual Meeting
February 13th, 2025
Novita to Present Additional Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at American Association for Cancer Research Immuno-Oncology Conference 2025 (AACR IO) Annual Meeting
May 28, 2024
Novita to Present First-in-Class Fascin Inhibitor NP-G2-044 Phase 2 Results in Patients with Advanced and Metastatic Solid Tumors at 2024 ASCO Annual Meeting
December 15, 2021
Novita Pharmaceuticals Doses First Patient in Phase 1B-2A Clinical Study of NP-G2-044 in Patients with Advanced or Metastatic Solid Tumor Malignancies
July 28, 2021
Novita Pharmaceuticals and China Resources Double Crane Pharmaceutical Enter into an Exclusive License Agreement to Develop and Commercialize Fascin Inhibitor in China
May 20, 2021
Novita Pharmaceuticals to Present its Fascin Inhibitor NP-G2-044 Phase 1A Results in Patients with Advanced and Metastatic Solid Tumors at 2021 ASCO Annual Meeting
© 2023 Novita Pharmaceuticals, Inc. | Site Design by Digital Elevator